Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

PHASE4TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

July 14, 2020

Study Completion Date

July 14, 2020

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Acthar Gel

Acthar Gel 1 mL (80U) for subcutaneous injection

DRUG

Placebo

Placebo for subcutaneous injection

Trial Locations (22)

14215

University of Buffalo, Buffalo

27157

Wake Forest University School of Medicine, Winston-Salem

30327

Multiple Sclerosis Center of Atlanta, Atlanta

31405

Meridian Clinical Research LLC, Savannah

32308

Tallahassee Neurological Clinic, PA, Tallahassee

32751

Neurology Associates, P. A., Maitland

33136

University of Miami - Miller School of Medicine, Miami

34205

University of South Florida, Bradenton

44195

The Cleveland Clinic Foundation, Cleveland

44870

Northern Ohio Neuroscience, LLC, Sandusky

45417

University of Cincinnati Physicians Company, LLC, Dayton

46804

Fort Wayne Neurological Center, Fort Wayne

60062

Consultants in Neurology LTD, Northbrook

61603

OSF Healthcare System Saint Francis Medical Center, Peoria

66160

University of Kansas Medical Center Research Institute, Inc., Kansas City

75214

Texas Neurology, PA, Dallas

78258

Neurology Center of San Antonio, San Antonio

80528

Advanced Neurosciences Research LLC, Fort Collins

87131

University of New Mexico, Albuquerque

94304

Stanford University Medical Center, Palo Alto

97205

Wayne State University (WSU) - Multiple Sclerosis Treatment and Clinical Research Center (MS Center), Detroit

98405

MultiCare Neuroscience Center of WA, Tacoma

Sponsors
All Listed Sponsors
lead

Mallinckrodt ARD LLC

INDUSTRY